These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20191432)

  • 1. Phosphodiesterase Targets for Cognitive Dysfunction and Schizophrenia--a New York Academy of Sciences Meeting.
    Zhang HT
    IDrugs; 2010 Mar; 13(3):166-8. PubMed ID: 20191432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDE inhibition and cognition enhancement.
    Blokland A; Menniti FS; Prickaerts J
    Expert Opin Ther Pat; 2012 Apr; 22(4):349-54. PubMed ID: 22475506
    [No Abstract]   [Full Text] [Related]  

  • 3. Phosphodiesterase inhibitors as potential cognition enhancing agents.
    Schmidt CJ
    Curr Top Med Chem; 2010; 10(2):222-30. PubMed ID: 20166957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia.
    Al-Nema MY; Gaurav A
    Curr Top Med Chem; 2020; 20(26):2404-2421. PubMed ID: 32533817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction.
    Duinen MV; Reneerkens OA; Lambrecht L; Sambeth A; Rutten BP; Os JV; Blokland A; Prickaerts J
    Curr Pharm Des; 2015; 21(26):3813-28. PubMed ID: 26044976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of renal ecto-phosphodiesterase.
    Jackson EK; Ren J; Zacharia LC; Mi Z
    J Pharmacol Exp Ther; 2007 May; 321(2):810-5. PubMed ID: 17308037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychiatric aspects of phosphodiesterases: An overview.
    Murthy VS; Mangot AG
    Indian J Pharmacol; 2015; 47(6):594-9. PubMed ID: 26729948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models.
    Shiraishi E; Suzuki K; Harada A; Suzuki N; Kimura H
    J Pharmacol Exp Ther; 2016 Mar; 356(3):587-95. PubMed ID: 26675680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase inhibition in cognitive decline.
    García-Barroso C; Ugarte A; Martínez M; Rico AJ; Lanciego JL; Franco R; Oyarzabal J; Cuadrado-Tejedor M; García-Osta A
    J Alzheimers Dis; 2014; 42 Suppl 4():S561-73. PubMed ID: 25125473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Prickaerts J; Heckman PRA; Blokland A
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1033-1048. PubMed ID: 28772081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase: an interface connecting cognitive deficits to neuropsychiatric and neurodegenerative diseases.
    Wang ZZ; Zhang Y; Zhang HT; Li YF
    Curr Pharm Des; 2015; 21(3):303-16. PubMed ID: 25159069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview.
    Heckman PR; Wouters C; Prickaerts J
    Curr Pharm Des; 2015; 21(3):317-31. PubMed ID: 25159073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
    Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
    Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of phosphodiesterases in schizophrenia : therapeutic implications.
    Siuciak JA
    CNS Drugs; 2008; 22(12):983-93. PubMed ID: 18998737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research.
    Jankowska A; Świerczek A; Wyska E; Gawalska A; Bucki A; Pawłowski M; Chłoń-Rzepa G
    Curr Drug Targets; 2019; 20(1):122-143. PubMed ID: 30091414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor.
    Macek TA; Suzuki K; Asin K; Kimura H
    Int J Neuropsychopharmacol; 2020 Nov; 23(8):524-532. PubMed ID: 32598478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase 10 (PDE10) inhibitors: an updated patent review (2014-present).
    Zagórska A
    Expert Opin Ther Pat; 2020 Feb; 30(2):147-157. PubMed ID: 31874060
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia.
    Cutshall NS; Onrust R; Rohde A; Gragerov S; Hamilton L; Harbol K; Shen HR; McKee S; Zuta C; Gragerova G; Florio V; Wheeler TN; Gage JL
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5595-9. PubMed ID: 22841436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDE10A inhibitors: novel therapeutic drugs for schizophrenia.
    Kehler J; Nielsen J
    Curr Pharm Des; 2011; 17(2):137-50. PubMed ID: 21355834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.